Market Competition

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

The Phase 3 result positions the TROP2‑targeting ADC for regulatory filings, potentially shifting first‑line care for patients who cannot receive immunotherapy.